Nomura Holdings’s Summit Therapeutics SMMT Stock Holding History

Nomura Holdings’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.95M	Sell	313,981 -228,253	-42%	-$3.69M	0.02%	590
2025 Q4	$9.48M	Sell	542,234 -506,693	-48%	-$9.53M	0.01%	532
2025 Q3	$21.7M	Buy	1,048,927 +1,004,971	+2,286%	+$24.4M	0.03%	299
2025 Q2	$935K	Buy	+43,956	New	+$1M	﹤0.01%	1022
2024 Q4	–	Sell	-18,967	Closed	-$415K	–	2381
2024 Q3	$415K	Buy	+18,967	New	+$265K	﹤0.01%	1290
2023 Q2	–	Sell	-47,971	Closed	-$83.9K	–	1610
2023 Q1	$83.9K	Buy	+47,971	New	+$131K	﹤0.01%	1309

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nomura Holdings's SMMT Position: Q1 2026 in Review

Nomura Holdings reduced its Summit Therapeutics (SMMT) stake by 42% in Q1 2026, selling an estimated $3.69M and leaving 313,981 shares worth $5.95M. The position accounts for 0.02% of the portfolio, ranked #590.

Nomura Holdings first reported a position in SMMT in Q1 2023 and has held it in 6 quarters since. The position peaked at $21.7M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Nomura Holdings held 313,981 shares of Summit Therapeutics worth $5.95M as of Q1 2026.
Nomura Holdings sold 228,253 Summit Therapeutics shares in Q1 2026, an estimated $3.69M.
Summit Therapeutics made up 0.02% of Nomura Holdings's portfolio in Q1 2026, its #590 holding.
Nomura Holdings first reported a position in Summit Therapeutics in Q1 2023 and has held it in 6 quarters since.
Nomura Holdings's Summit Therapeutics position peaked at $21.7M in Q3 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.